Edition:
United States

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

4.20USD
4:00pm EDT
Change (% chg)

$0.15 (+3.70%)
Prev Close
$4.05
Open
$4.15
Day's High
$4.30
Day's Low
$4.10
Volume
89,501
Avg. Vol
60,535
52-wk High
$5.25
52-wk Low
$1.10

Latest Key Developments (Source: Significant Developments)

Cancer Genetics and Mendel.ai announce strategic partnership
Monday, 3 Apr 2017 07:00am EDT 

Cancer Genetics Inc : Cancer Genetics, Inc. and Mendel.ai announce strategic partnership enabling artificial intelligence in precision medicine to drive personalized treatment and accelerate clinical trial matching for cancer care .Cancer Genetics - expect that initial partners will be using Mendel.ai system during Q2 of 2017 with wider rollout through Q3 and Q4 of this year.  Full Article

Cancer Genetic Q4 loss per share $0.15
Thursday, 23 Mar 2017 07:30am EDT 

Cancer Genetics Inc : Cancer Genetics, Inc. Announces record revenue for fourth quarter and full-year 2016 and provides 2017 business update . Q4 loss per share $0.15 .Q4 revenue rose 32 percent to $7.2 million.  Full Article

Cancer Genetics selected by BeiGene to collaborate on clinical trial services, advance portfolio of Novel Oncology Therapeutics
Wednesday, 7 Dec 2016 07:54am EST 

Cancer Genetics Inc :Cancer Genetics, Inc is selected by BeiGene, Ltd to collaborate on clinical trial services & advance portfolio of Novel Oncology Therapeutics.  Full Article

Cancer Genetics receives New York state approval for Focus::Myeloid NGS-based panel
Wednesday, 17 Aug 2016 07:30am EDT 

Cancer Genetics Inc :Received New York state approval for its Focus::Myeloid NGS-based panel for Myeloid malignancies.  Full Article

Cancer Genetics Q1 revenue rose 39 pct to $6.1 mln
Tuesday, 10 May 2016 04:01pm EDT 

Cancer Genetics Inc : Cancer Genetics Inc announces 39% revenue increase and provides recent company highlights .Q1 revenue rose 39 percent to $6.1 million.  Full Article

Cancer Genetics announces closing of $12 million public offering
Thursday, 12 Nov 2015 09:38pm EST 

Cancer Genetics:Confirmed the closing of its previously announced public offering of 3,000,000 shares of its common stock with five-year warrants to purchase 3,000,000 shares of common stock at an exercise price of $5.00 per share at a combined price to the public of $4.00.Cancer Genetics' gross proceeds from this offering were $12.0 million before deducting underwriting discounts and commissions, as well as other estimated offering expenses payable by Cancer Genetics.Says underwriters were granted a 45-day option to purchase up to an aggregate of 450,000 additional shares of common stock and/or warrants.Says the underwriters' option to purchase additional warrants was exercised and sold today.Joseph Gunnar & Co., LLC and Feltl and Company, Inc. acted as the joint book-running managers for the offering.Axiom Capital Management, Inc. acted as co-manager for the offering.Says net proceeds of the offering are estimated to be approximately $10.5 million, after deducting underwriting discounts and commissions and estimated offering expenses.Cancer Genetics intends to use the net proceeds from the offering for the integration of recent acquisitions; sales and marketing to support new product launches; and to fund contributions to OncoSpire, Cancer Genetics' joint venture with the Mayo Clinic.  Full Article

Cancer Genetics, Inc prices public offering of securities
Friday, 6 Nov 2015 06:45am EST 

Cancer Genetics, Inc:Prices public offering of securities.Says public offering of 3 million common shares priced at $4.00 per share.  Full Article

Cancer Genetics, Inc Announces Agreement in principle to acquire the Assets of Response Genetics, Inc
Monday, 10 Aug 2015 09:51am EDT 

Cancer Genetics, Inc:Announces agreement in principle to acquire the assets of Response Genetics Inc and its strong franchise in solid tumor molecular and genomic testing.Response Genetics is expected to contribute an additional $10 to $12 million to cgi in revenue over the next 12 months.Says Response Genetics has filed a voluntary petition under chapter 11 of the bankruptcy code in the Delaware bankruptcy court.  Full Article

Cancer Genetics Inc announces agreement with harvard pilgrim healthcare
Thursday, 16 Jul 2015 07:00am EDT 

Cancer Genetics Inc:Announces the expansion of access to its proprietary diagnostic tests through agreement with harvard pilgrim healthcare.Says under terms, cgi will offer Cancer diagnostic services to individuals covered under harvard pilgrim plans.  Full Article

Cancer Genetics, Inc announces partnership with ICON's Laboratory Services
Tuesday, 7 Jul 2015 07:00am EDT 

Cancer Genetics, Inc:Says that it has entered into a partnership with the Laboratory Services group of ICON plc, the global CRO.The partnership will provide clients access to combined expertise ranging from complex, oncology-focused genomic testing to core central laboratory analysis, project and data management and sample logistics on a global basis.  Full Article

More From Around the Web

BRIEF-Cancer Genetics and Mendel.ai announce strategic partnership

* Cancer Genetics, Inc. and Mendel.ai announce strategic partnership enabling artificial intelligence in precision medicine to drive personalized treatment and accelerate clinical trial matching for cancer care